What is/are Zafirlukast?
Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), taken once daily. Zileuton (Zyflo), also used in the treatment of asthma via its inhibition of 5-lipoxygenase, is taken four times per day.
Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.
Zafirlukast is marketed by Astra Zeneca with the brand names Accolate, Accoleit, and Vanticon. It was the first LTRA to be marketed in the USA and is now approved in over 60 countries, including the UK, Japan, Taiwan, Italy, Spain, Canada, Brazil, China and Turkey.
- Worsening asthma symptoms;
- New or worsening cough, fever, trouble breathing;
- Mood or behavior changes, anxiety, depression, sleep problems (insomnia);
- Skin rash, bruising, severe tingling, numbness, pain, muscle weakness; or
- Nausea, pain in your upper stomach, loss of appetite, flu symptoms, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Less serious side effects of zafirlukast may include:
- Diarrhea, stomach pain;
- Muscle pain; or
- Sore throat, cold symptoms.
This article uses material from the Wikipedia article Zafirlukast, which is released under the Creative Commons Attribution-Share-Alike License 3.0.